Stryker (NYSE:SYK) Stock Price Target Cut by BTIG Research

Stryker (NYSE:SYK) had its target price decreased by equities researchers at BTIG Research from $358.00 to $316.00 in a research report issued on Monday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the medical technology company’s stock. BTIG Research’s target price points to a potential upside of 11.81% from the stock’s previous close.

A number of other analysts have also weighed in on SYK. Citizens Jmp lowered their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Truist Financial cut their target price on shares of Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a research report on Tuesday, October 6th. BMO Capital Markets restated an “outperform” rating and issued a $317.00 price target on shares of Stryker in a report on Wednesday, September 9th. Stifel Nicolaus reduced their price target on shares of Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Finally, Piper Sandler lowered their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Stock Up 0.0%

Shares of NYSE:SYK opened at $282.63 on Monday. The business’s 50 day moving average is $302.18 and its 200 day moving average is $313.58. The stock has a market cap of $108.41 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 1.79 and a beta of 0.78. Stryker has a 52-week low of $267.00 and a 52-week high of $392.55. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the company posted $3.13 EPS. Stryker’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker will post 14.96 EPS for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Perpetual Ltd raised its stake in shares of Stryker by 17,298.2% during the 3rd quarter. Perpetual Ltd now owns 338,569 shares of the medical technology company’s stock worth $93,239,000 after acquiring an additional 336,623 shares in the last quarter. Rockland Trust Co. boosted its stake in Stryker by 1.1% in the third quarter. Rockland Trust Co. now owns 3,365 shares of the medical technology company’s stock valued at $927,000 after acquiring an additional 36 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Stryker by 22.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 10,436 shares of the medical technology company’s stock valued at $3,286,000 after acquiring an additional 1,915 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Stryker by 12.2% in the second quarter. Envestnet Asset Management Inc. now owns 650,461 shares of the medical technology company’s stock worth $204,790,000 after purchasing an additional 70,634 shares during the last quarter. Finally, State Street Corp grew its holdings in Stryker by 1.2% in the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after purchasing an additional 183,400 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker announced an approximately $400 million investment in CMR Surgical, along with exclusive U.S. sales rights for CMR’s Versius soft-tissue surgical robot and an option to acquire the company. The deal expands Stryker’s presence in robotic-assisted surgery, broadens its product portfolio beyond orthopedics, and could leverage Stryker’s commercial infrastructure to accelerate Versius adoption. Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
• Positive Sentiment: Leerink Partners reiterated its Buy rating on Stryker, indicating that the analyst remains constructive on the company’s growth outlook despite recent share-price weakness. Leerink Partners Sticks to Its Buy Rating for Stryker
• Neutral Sentiment: The CMR transaction is strategically attractive but requires significant upfront capital and carries execution, regulatory and commercialization risks. Its financial contribution is likely to build over time rather than immediately improve earnings.
• Negative Sentiment: BTIG Research lowered its Stryker price target from $358 to $316, although it maintained a Buy rating. The reduced target signals more limited near-term upside and may weigh on investor sentiment. Stryker Makes $400 Million Robotic Surgery Bet
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Stryker investors. The announcement does not establish wrongdoing, but securities-law investigations can add headline risk and uncertainty around the stock. Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.